Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

PerPrev-CID Personalized disease prediction and prevention in chronic inflammatory disorders

Coordinator
Universitatsklinikum Schleswig-Holstein, Germany
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€11.0m
Total cost
—
Partners
15 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101156542

What the project is doing

In the project's own words, from its summary on CORDIS.

Background: Chronic inflammatory diseases (CID) are a group of non-communicable disorders of the immune system with a lifetime prevalence of over 10% in the EU. Rheumatoid arthritis (RA) and inflammatory bowel diseases (IBD) are two archetypal CIDs with a particularly high unmet medical need and impact on European health care systems. Objectives: The PerPrev-CID consortium aims to set up new standards for decision support tool development for preventive and early therapeutic interventions in RA and IBD.

Selected main aims are: (i) To define actionable predictors from longitudinal multi-level Omics and clinical data integration In RA and IBD. We will identify markers indicating progression from pre-symptomatic to manifest disease and signatures predicting early disease relapse (ii) To develop new tools for home-based and continuous assessment of patient-related data dimensions using digital health apps/wearables, including more innovative, objective parameters, such as movement patterns, physical activity, and sleep. (iii) To assess the health-promoting effects of interfering with the tryptophan pathway in a proof-of-concept nutritional study in early RA and IBD. (iv) To study ethical, legal and economic consequences of risk assessment and early low-threshold preventive interventions.

Important aspects are the communication of the risk concept, economic implications of broad testing and interventions as well as patients´ perception of the concept of risk prediction. Expected impact: We will develop prototype solutions for privacy-preserving AI-based data analysis for research and clinical application and will test a first proof-of-concept low threshold intervention in RA and IBD. Our approaches will provide a clear health benefit to the citizens of the EU by improving health outcomes, empowering joint decision making and contributing to appropriate action plans to reduce the avoidable burden of the diseases.

Who is involved

OrganisationCityCountryRole
Universitatsklinikum Schleswig-HolsteinLübeckGermanyCoordinator
International Federation of Crohn's and Ulcerative Colitis AssociationsBruxelles / BrusselBelgiumParticipant
Universite De LiegeLiegeBelgiumParticipant
Vib VzwZwijnaarde - GentBelgiumParticipant
European Alliance of Associations for RheumatologyZurichSwitzerlandAssociatedpartner
Universite De GeneveGeneveSwitzerlandAssociatedpartner
Christian-Albrechts-Universitaet Zu KielKielGermanyThird party
Deutsches Zentrum Fur Neurodegenerative Erkrankungen eVBonnGermanyParticipant
Eurice European Research and Project Office GmbHSt IngbertGermanyParticipant
Weizmann Institute of ScienceRehovotIsraelParticipant
Universita Cattolica Del Sacro CuoreMilanoItalyParticipant
Lietuvos Sveikatos Mokslu UniversitetasKaunasLithuaniaParticipant
Lietuvos Sveikatos Mokslu Universiteto Ligonine Kauno KlinikosKaunasLithuaniaThird party
Stichting Radboud UniversiteitNijmegenNetherlandsParticipant
The University of ManchesterManchesterUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI